Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma Meeting Abstract
| Authors: | Batlevi, C. L.; Park, S. I.; Phillips, T. J.; Amengual, J.; Andorsky, D. J.; Campbell, P.; McKay, P.; Leonard, J. P.; Sondhi, M.; Yang, J.; Chen, Y.; O'Connor, H.; Slatcher, P.; Morschhauser, F. |
| Abstract Title: | Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302032 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7572 |
| Notes: | Meeting Abstract: 7572 -- This meeting was also held virtually -- Source: Wos |
